{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Baseline (IgA)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.8"}]}],"title":"Week 16 (IgA)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"2.2"}]}],"title":"Week 24 (IgA)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.7"}]}],"title":"Week 40 (IgA)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3.6"}]}],"title":"Week 52 (IgA)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"6.0"}]}],"title":"Baseline (IgG)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"},{"groupId":"OG001","value":"1.8"}]}],"title":"Week 16 (IgG)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"2.2"}]}],"title":"Week 24 (IgG)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"0"}]}],"title":"Week 40 (IgG)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"0"}]}],"title":"Week 52 (IgG)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6"},{"groupId":"OG001","value":"11.9"}]}],"title":"Baseline (IgM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"},{"groupId":"OG001","value":"23.2"}]}],"title":"Week 16 (IgM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1"},{"groupId":"OG001","value":"28.3"}]}],"title":"Week 24 (IgM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8"},{"groupId":"OG001","value":"24.3"}]}],"title":"Week 40 (IgM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8"},{"groupId":"OG001","value":"28.6"}]}],"title":"Week 52 (IgM)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"groups":[{"description":"Participants received rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met. Participants also received MMF matching placebo orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52.","id":"OG000","title":"Rituximab (RTX)"},{"description":"Participants received Mycophenolate Mofetil (MMF) orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants also received rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria had been met.","id":"OG001","title":"Mycophenolate Mofetil (MMF)"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who were randomized and received any part of an infusion of study drug or oral administration of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline; Weeks 16, 24, 40 and 52; (end of treatment: up to Week 52) (up to CCOD of 28 November 2018)","title":"Percentage of Participants With Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}